Technology | Quality Assurance (QA) | July 10, 2019

IBA Launches Monte Carlo Patient QA for Varian Halcyon at AAPM 2019

New SciMoCa Monte Carlo patient QA enables fast and efficient quality assurance accuracy for Varian Halcyon in addition to all other major radiation therapy systems

IBA Launches Monte Carlo Patient QA for Varian Halcyon at AAPM 2019

July 10, 2019 — IBA announced the launch of the latest functionality of the SciMoCa Monte Carlo Patient QA solution at the 61st annual American Association of Physicists in Medicine (AAPM) annual meeting, July 14-18 in San Antonio, Texas. The new release of SciMoCa provides what IBA calls the first and only worldwide commercial Monte Carlo Patient QA for the Varian Halcyon System.

Healthcare professionals can now verify all Halcyon treatment plans independently, accurately, and with an automated and efficient workflow. The fast Monte Carlo dose calculation enables highly accurate results even for the most challenging cases like non-coplanar stereotactic body radiation therapy (SBRT), and in particular for indications with tissue inhomogeneity like lung and head & neck treatments.

Monte Carlo is the gold standard for dose calculation accuracy in treatment planning. With SciMoCa, the accuracy of Monte Carlo is now available for independent secondary dose calculation and patient QA (quality assurance) as well, allowing users to verify the most advanced treatment plans with an equally robust and fast QA solution. SciMoCa is used clinically for all standard linear accelerator (linac) types, for the Accuray CyberKnife and TomoTherapy/Radixact, and is now also compatible with Varian Halcyon.

The high-quality beam models for SciMoCa are created linac-specific for customers applying dedicated processes, expert tools and experience. This process allows an independent verification of the commissioning data and the TPS model, providing an additional level of peace of mind about the accuracy of the machine and TPS commissioning. This is particularly valuable for pre-commissioned treatment machines like Halcyon.

The SciMoCa software is manufactured by Radialogica LLC and globally distributed by IBA Dosimetry.

For more information:

Related Content

Varian announced it has received FDA 510(k) clearance for its Ethos therapy, an Adaptive Intelligence solution. Ethos therapy is an artificial intelligence (AI)-driven holistic solution that provides an opportunity to transform cancer care.
News | Image Guided Radiation Therapy (IGRT) | February 11, 2020
February 11, 2020 — Varian announced it has received FDA 510(k) c
The radiation therapy market is projected to grow in through 2026

Image courtesy of Accuray

News | Proton Therapy | February 10, 2020
February 10, 2020 — Amid technological advancement, and notable research and development activities, the global ...
SIR President Laura Findeiss, M.D., FSIR

SIR President Laura Findeiss, M.D., FSIR

News | Interventional Radiology | February 09, 2020
February 9, 2020 — For some patients, kidney cancer can be effectively treated without surgery, according to the...
Accuray TomoTherapy total body irradiation
News | Radiation Therapy | February 07, 2020
February 7, 2020 — Accuray Incorporated announced that two new studies demonstrate the benefits of the ...
Purdue University-discovered fluorescent markers to target and illuminate cancer during surgery, has announced the results of a multi-institutional Phase 2 clinical trial in which outcomes were improved for 26 percent of patients undergoing pulmonary resection for non-small-cell lung cancer (NSCLC)

A Purdue discovery being developed by On Target Laboratories Inc., illuminates lung cancer cells on a patient during surgery. The “fluorescent markers” help medical professionals identify and remove cancer cells during surgery and is shown to improve outcomes. The technology is beginning Phase 3 clinical trials. (Photo provided by On Target)

News | Molecular Imaging | February 06, 2020
February 6, 2020 — ...
The luminescent oxygen probe PtG4 is injected during the week of radiation treatment and localizes between the cells of the tumor as illustrated by microscopy

An oxygen map image recovered from a mouse undergoing radiation therapy. The luminescent oxygen probe PtG4 is injected during the week of radiation treatment and localizes between the cells of the tumor as illustrated by microscopy (red). Image courtesy of Brian Pogue, PhD

News | Radiation Therapy | February 03, 2020
February 3, 2020 — Oxygen in cancer tumors is known to be a major factor that helps radiation therapy be successful.
News | Clinical Trials | February 03, 2020
February 3, 2020 — Melding the genetic and cellular analysis of tumors with how they appear in medical images could g
Elekta Unity MR Linac system
News | Radiation Oncology | January 30, 2020
January 30, 2020 — Elekta announced that it signed a contract wit
Automated Triage of Thyroid Cancer

73-year-old man with papillary carcinoma of left lobe of thyroid. Screen shot shows example of thyroid nodule annotation (segmentation and TI-RADS annotation) performed on ultrasound image in longitudinal projection with electronic Physician Annotation Device software (Stanford Medicine Radiology). Radiologists performed nodule segmentation by selecting points (red) on nodule outline (green), while controlling smoothing of outline polygon by means of spline interpolation.

News | Ultrasound Imaging | January 30, 2020
January 30, 2020 — According to an ar...